• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics…of Peptides and P-ANDAS

by Annie De Groot | Oct 30, 2018 | 0 comments

EpiVax_EuroTIDES_PANDA_02Nov18

To learn more about EpiVax’s PANDA Program, read our latest entries.

  • PANDA screening
  • Interview with Brian Roberts: Protein Therapeutics Manager
  • PANDA Press Release

Submit a Comment

You must be logged in to post a comment.

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar
  • Is “Artificial” Intelligence an Option for your ADA ?

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline